Identification and validation of targets for cancer immunotherapy: from the bench-to-bedside [PDF]
, 2013 Chapter 12 in Novel Gene Therapy ...
Brooks, Suzanne E. +4 more
core +3 more sources
Effect of chemotherapy on passenger mutations in metastatic colorectal cancer
Molecular Oncology, EarlyView.Changes in passenger mutation load and predicted immunotherapy response after chemotherapy treatment. Tumor cells rich with passenger mutations have increased sensitivity to chemotherapy. Correlation of passenger mutations with neoantigen load suggests highly mutated clones promote a more effective response to immunotherapy, and therefore, first‐line ...
Marium T. Siddiqui +6 more
wiley +1 more source
Dual targeting of RET and SRC synergizes in RET fusion‐positive cancer cells
Molecular Oncology, EarlyView.Despite the strong activity of selective RET tyrosine kinase inhibitors (TKIs), resistance of RET fusion‐positive (RET+) lung cancer and thyroid cancer frequently occurs and is mainly driven by RET‐independent bypass mechanisms. Son et al. show that SRC TKIs significantly inhibit PAK and AKT survival signaling and enhance the efficacy of RET TKIs in ...
Juhyeon Son +13 more
wiley +1 more source
CD24 signalling through macrophage Siglec-10 is a new target for cancer immunotherapy
Nature, 2019 Ovarian cancer and triple-negative breast cancer are among the most lethal diseases affecting women, with few targeted therapies and high rates of metastasis. Cancer cells are capable of evading clearance by macrophages through the overexpression of anti-
Amira A. Barkal +10 more
semanticscholar +1 more source
Escape from immunotherapy: possible mechanisms that influence tumor regression/progression [PDF]
, 2004 Tumor escape is one major obstacle that has to be addressed prior to designing and delivering successful immunotherapy. There is compelling evidence to support the notion that immunogenic tumors, in murine models and cancer patients, can be rejected by ...
Ahmad, M, Ali, SA, Rees, RC
core +1 more source
Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the Netherlands [PDF]
, 2021 Christine M. Cramer‐van der Welle +14 more
openalex +1 more source
Molecular Oncology, EarlyView.We developed and validated a DNA methylation–based biomarker panel to distinguish pleural mesothelioma from other pleural conditions. Using the IMPRESS technology, we translated this panel into a clinically applicable assay. The resulting two classifier models demonstrated excellent performance, achieving high AUC values and strong diagnostic accuracy.
Janah Vandenhoeck +12 more
wiley +1 more source
Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab
Journal of Translational Medicine, 2017 Background Nivolumab is an anti-PD1 checkpoint inhibitor active in patients with advanced melanoma and as adjuvant therapy in high-risk metastatic melanoma patients.
Silvana Morello +8 more
doaj +1 more source
Cancer vaccines: uses of HLA transgenic mice compared to genetically modified mice [PDF]
, 2008 Many tumor antigens have been identified that can be targeted by the immune system. Animal models that have been genetically modified to express human HLA molecules instead of their own MHC antigens have shown to be valuable in the discovery of peptides ...
McArdle, SE
core